Modified Target Delineation and Moderately Hypofractionated Radiotherapy for High-Grade Glioma

Does modified target delineation combined with moderately hypofractionated simultaneous boost intensity-modulated radiotherapy (HSIB-IMRT) improve the clinical outcomes for patients with newly diagnosed high-grade glioma (HGG)?In this randomized clinical trial of 154 patients with HGG, modified target delineation combined with moderately HSIB-IMRT did not improve progression-free or overall survival; however, it significantly reduced the irradiation target volume compared with standard IMRT. The experimental approach demonstrated equivalent efficacy to standard IMRT, without increasing the recurrence outside the target volume.These results suggest that modified target delineation combined with HSIB-IMRT provides clinical efficacy comparable to standard IMRT for newly diagnosed HGG compared with the potential for reduced irradiation volumes.

Corresponding Authors: Guanghui Li, MD, PhD, Cancer Research Institute of the Chinese People’s Liberation Army (liguanghui_2000@aliyun.com), and Shengqing Lv, MD, PhD, Department of Neurosurgery (lvsq0518@hotmail.com), Xinqiao Hospital, Army Medical University, No. 183 Xinqiao St, Shapingba District, Chongqing City 400037, People’s Republic of China.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.